BTIG Research Boosts Novogen (NASDAQ:KZIA) Price Target to $40.00

Novogen (NASDAQ:KZIA) had its target price boosted by equities researchers at BTIG Research from $34.00 to $40.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s target price indicates a potential upside of 211.62% from the company’s current price.

KZIA has been the subject of a number of other reports. Canaccord Genuity Group assumed coverage on Novogen in a research report on Thursday, August 13th. They set a “buy” rating and a $29.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a report on Friday, July 17th. Finally, Lake Street Capital started coverage on Novogen in a research note on Thursday, June 11th. They set a “buy” rating and a $32.00 price target for the company. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.33.

Novogen Stock Performance

KZIA stock traded down $0.93 during trading on Tuesday, hitting $12.84. The company had a trading volume of 343,611 shares, compared to its average volume of 219,009. Novogen has a 1-year low of $4.86 and a 1-year high of $17.40. The firm has a 50-day moving average price of $13.47 and a 200-day moving average price of $11.31.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.